Navigation Links
Cardica Updates Enrollment Progress In European Clinical Trial
Date:2/27/2013

utter XPRESS™ 30, a true multi-fire laparoscopic stapling device. Both MicroCutter devices are designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 30 and XPRESS 30 products require 510(k) review and are not yet commercially available in the U.S. 

Forward-Looking Statements

The statement in this press release regarding Cardica's plans to complete enrollment in the European clinical trial in the second quarter of calendar year 2013,  is a "forward-looking statement." There are a number of important factors that could cause Cardica's results to differ materially from those indicated by this forward-looking statement, including:  that the XCHANGE 30 may face development, regulatory and manufacturing risks; that surgeons may not use the XCHANGE 30 correctly, which could cause unfavorable results that may impair the acceptance of the XCHANGE 30 by other surgeons or otherwise delay completion of enrollment; and that Cardica may not have sufficient funds to complete enrollment in the clinical trial, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Current Report on Form 10-Q for the quarter ended December 31, 2012. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cardica Announces Fiscal 2012 Third Quarter Financial Results
2. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
3. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
4. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
5. Cardica Announces Fiscal 2013 First Quarter Financial Results
6. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
7. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
8. Cardica Announces Fiscal 2013 Second Quarter Financial Results
9. Neuralstem Updates ALS Stem Cell Trial Progress
10. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
11. TPI Provides Further Updates on its GMOL Flagship Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)... , March 27, 2015  WebMD ... leading source of health information, today announced ... new National Action Plan for Combating ... Obama emphasized the urgency and importance of ... national and global health.    The ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... HAMILTON, Bermuda , April 30 Celtic Pharmaceutical Holdings L.P. ... pharmaceutical industries, announced today the enrolment of the first patient into its ... treatment of onychomycosis (also known as a fungal nail infection).   , ... This Phase III trial is ...
... , April 29 Abraxis BioScience initially ... the former ICN/Valient Pharmaceutical building in Costa Mesa, ... foot building. The "due diligence report" revealed an array ... occupying the building, and once the building purchase was ...
Cached Medicine Technology:Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 3Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 4LCS Constructors, Inc. Completes First Major Phase of Abraxis BioScience Project 2
(Date:3/28/2015)... March 28, 2015 The "Petrick ... of sustainable health. After 18 years of research and ... professional UFC contenders, Dr. Jon Petrick is excited to ... Just some of the immediate benefits of this radical ... increased levels of strength of the immune system, faster ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... In her mid-forties and with a lifelong ... Monica K. arrived at JET Uniform & Supply ... and scared. The owners and staff at JET, which had ... to offer jobs to challenged residents like Monica, were patient. ... to begin with the end in mind,” says Stephen Milaney, ...
(Date:3/27/2015)... Kansas City, Mo (PRWEB) March 27, 2015 ... common complications for patients undergoing percutaneous coronary intervention ... Ironically, studies have observed a “risk-treatment paradox,” in ... to gain from treatment are treated less often ... , Researchers at Saint Luke’s Mid America Heart ...
(Date:3/27/2015)... 27, 2015 Ticket Down is a reputable source ... 2015. After a phenomenal and highly successful live tour last ... going out on tour again in 2015 and they will be ... on April 29th in New York City at the cozy Beacon ... Theatre on May 10th. , Fans of the hit show can ...
Breaking Medicine News(10 mins):Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... for the treatment of human viral,and other infectious ... quarter and year ended December 31, 2007. At ... securities totaled,$112.0 million., Significant ...
... March 6, 2008 A study released this ... Healthcare System in California shows that non-polypoid colorectal neoplasms ... than previously thought and may have a greater association ... commonly diagnosed colorectal polyp. The study appears in the ...
... of nursing would,help address the severe nurse faculty ... WASHINGTON, March 6 Today, the American,Association ... Durbin,(D-IL) for introducing the Troops to Nurse Teachers ... when the military and civilian healthcare systems have,been ...
... A study released,this week from researchers at ... shows that non-polypoid colorectal neoplasms or flat,colon lesions, ... and may,have a greater association with cancer compared ... polyp. The study appears in the,March 5 issue ...
... DALLAS, March 6 State Medicaid programs ... innovative,initiative of Affiliated Computer Services, Inc. (NYSE: ... ACS, healthcare clients avoid costly,manual recovery of drug ... enables pharmacies to immediately identify pharmacy,benefit coverage at ...
... offers hope of new diabetes treatments , , THURSDAY, ... levels disable the molecular switch that normally turns off ... insulin levels, a California study finds. , This ... the "sugar-off" switch (CRTC2) may help lower glucose levels ...
Cached Medicine News:Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 8Health News:Colonoscopy used to identify and remove flat colon lesions 2Health News:AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008 2Health News:AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008 3Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 2Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 3Health News:Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study 4Health News:ACS Launches Medicaid Cost Savings Initiative 2Health News:ACS Launches Medicaid Cost Savings Initiative 3Health News:Constant High Blood Sugar Disables Insulin 'Off' Switch 2
... including aspiration holes and additional electrode ... requiring precise dissection with decreased risk ... demands. ,Flexible design options allow ... electrodes and multiple tip designs. Optimize ...
... Enhanced features including aspiration holes and ... laparoscopic procedures requiring precise dissection with ... increased suction demands. ,Flexible design ... and nonretractable electrodes and multiple tip ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: